Is combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂?
The combination of rosuvastatin with sartans of different PPARγ-activating capacity did not differentiate alterations of LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass.
In STZ-induced diabetic rats, A. iva improves reverse cholesterol transport by enhancing LCAT activity, leading to anti-atherogenic effects.